2023
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists
Madanat Y, Zeidan A. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists. Clinics In Laboratory Medicine 2023, 43: 685-698. PMID: 37865511, DOI: 10.1016/j.cll.2023.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow biopsy reportsAvailable treatment optionsBest therapeutic approachClinical presentationPathologic findingsRisk stratificationTherapeutic optionsTreatment optionsBiopsy reportsDisease entityTherapeutic approachesTreatment considerationsAccurate diagnosisGenetic abnormalitiesDiagnosisDisease subclassificationPatientsNeoplasmsHematopathologistsOptionsPrognosticationAbnormalitiesCliniciansSubclassification
2022
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
Gurnari C, Xie Z, Zeidan A. How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms. Clinical Hematology International 2022, 5: 8-20. PMID: 36574201, PMCID: PMC10063738, DOI: 10.1007/s44228-022-00024-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMyelodysplastic syndromeMyelodysplastic neoplasmsInternational Prognostic Scoring SystemHematopoietic stem cell transplantManagement of cytopeniasNon-transplant treatmentTransplant-ineligible patientsBone marrow dysplasiaAvailable therapeutic optionsMinority of patientsNew investigational agentsPrognostic scoring systemStem cell transplantMain clinical problemLow-risk groupHigh-risk casesAcute myeloid leukemiaIneligible patientsMarrow dysplasiaCell transplantInvestigational agentsTherapeutic optionsClinical managementCurative approachMyeloid leukemiaAre We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia? Cancers 2022, 14: 2434. PMID: 35626039, PMCID: PMC9140008, DOI: 10.3390/cancers14102434.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationCD47/SIRPαIntensive induction therapyAvailable therapeutic optionsStem cell transplantationStandard of careAvailable clinical dataTesting of agentsInduction therapyMedian overallRefractory settingAggressive treatmentTim-3Immune checkpointsPreclinical rationaleTherapeutic optionsCell transplantationEfficacy dataClinical dataPatientsMolecular subgroupsTherapeutic agentsIn vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2
Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia 2022, 36: 1313-1323. PMID: 35273342, PMCID: PMC9103411, DOI: 10.1038/s41375-022-01536-x.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeMDS/acute myeloid leukemiaRefractory acute myeloid leukemiaPARP inhibitionVivo anti-tumor effectsAlternate therapeutic optionsSubset of AMLAnti-tumor effectsPre-clinical studiesRibose polymerase inhibitorsSerial transplantation assaysHomologous recombination defectsTherapeutic optionsTreatment optionsOverall engraftmentHigh relapseIDH inhibitionMyeloid leukemiaIsocitrate dehydrogenase 1Small molecule inhibitorsCell frequencyXeno-graftsIDH1/2 mutationsMalignant transformation
2018
Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place
Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review Of Hematology 2018, 11: 715-726. PMID: 30024293, DOI: 10.1080/17474086.2018.1503049.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmunosuppressive therapyMyelodysplastic syndromeImmune pathwaysManagement of MDSTreatment of MDSClonal hematopoietic stem cell disordersMeaningful clinical activityAdaptive immune pathwaysHematopoietic stem cell disordersStem cell disordersImmune dysregulationDisease coursePeripheral cytopeniasClinical benefitImmune activationTherapeutic optionsAplastic anemiaClinical activityHematologic diseasesCell disordersClinical experienceContinued clarificationLeukemic progressionTherapyPatientsHypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Advances 2018, 2: 923-932. PMID: 29685952, PMCID: PMC5916007, DOI: 10.1182/bloodadvances.2018016121.Peer-Reviewed Original ResearchConceptsOverall survivalRR-AMLMedian OSOlder acute myeloid leukemia patientsAcute myeloid leukemia patientsCR/CRiIncomplete count recoveryMedian overall survivalDecreased overall survivalBone marrow blastsReasonable therapeutic optionMyeloid leukemia patientsPredictors of responseImproved response ratesLarge international patient cohortInternational patient cohortGood responseComplete remissionHematologic improvementRefractory AMLMarrow blastsMedian ageCount recoveryFrontline treatmentTherapeutic options
2017
Management of myelofibrosis: JAK inhibition and beyond
Stahl M, Zeidan AM. Management of myelofibrosis: JAK inhibition and beyond. Expert Review Of Hematology 2017, 10: 459-477. PMID: 28395559, DOI: 10.1080/17474086.2017.1317590.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow fibrosisMarrow fibrosisAbnormal cytokine expressionClinical trial evidenceJAK2 V617F allele burdenErythropoiesis stimulating agentsNovel therapeutic optionsAnti-fibrosis agentsV617F allele burdenJAK2 inhibitor ruxolitinibNovel therapeutic agentsJAK2 V617F mutationConstitutional symptomsCytoreductive drugsSymptom burdenImmunomodulatory drugsSurvival improvementJAK1/2 inhibitorMF patientsTherapeutic optionsTrial evidenceCytokine expressionExtramedullary hematopoiesisPrognostic assessmentRuxolitinib monotherapyManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
Stahl M, Zeidan AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Review Of Hematology 2017, 10: 345-364. PMID: 28277851, DOI: 10.1080/17474086.2017.1297704.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsErythropoiesis stimulating agentsMyelodysplastic syndromeLR-MDSImmunosuppressive therapyTreatment modalitiesLower-risk myelodysplastic syndromesTGF-β pathway inhibitorCombination treatment modalitiesLR-MDS patientsPromising investigational agentsSubset of patientsAvailable therapeutic modalitiesGoals of careStandard therapeutic optionPredictors of responseCurrent treatment modalitiesAcute myeloid leukemiaQuality of lifeBone marrow failureRisk assessment toolSymptom controlBlood cytopeniasInvestigational agentsTherapeutic optionsClinical behavior
2016
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2016, 15: 60-87. PMID: 28040720, DOI: 10.6004/jnccn.2017.0007.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeNCCN Clinical Practice GuidelinesHigh-intensity therapyPresence of cytopeniasLow-intensity therapyClinical practice guidelinesVariable disease courseTreatment of anemiaBetter treatment guidanceSupportive careDisease courseTherapeutic optionsPractice guidelinesDiagnostic criteriaTreatment approachesMyeloid disordersHeterogenous groupMolecular abnormalitiesTreatment guidanceDiagnostic classificationPatientsSyndromeTherapyTreatmentGuidelines
2015
Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions
Kim TK, Gore SD, Zeidan AM. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. Seminars In Hematology 2015, 52: 172-183. PMID: 26111464, PMCID: PMC5785931, DOI: 10.1053/j.seminhematol.2015.04.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaMyeloid leukemiaTreatment of AMLPathogenesis of AMLDevelopment of AMLNormal physiologic developmentHistone deacetylase inhibitorsEpigenetic therapyDNA methylationHistone methylation/acetylationTherapeutic optionsClinical evaluationDNA methyltransferase inhibitorHistone tail modificationsInhibitor of histoneMethylation/acetylationPromising drugClinical practiceTherapeutic targetingMutant isocitrate dehydrogenasesDeacetylase inhibitorsActual DNA sequenceAberrant DNA methylationPhysiologic developmentImportant mechanism
2014
Stem cells in gastrointestinal cancers: The road less travelled.
Mikhail S, Zeidan A. Stem cells in gastrointestinal cancers: The road less travelled. World Journal Of Stem Cells 2014, 6: 606-13. PMID: 25426257, PMCID: PMC4178260, DOI: 10.4252/wjsc.v6.i5.606.Peer-Reviewed Original ResearchCancer stem cellsGastrointestinal malignanciesNew therapeutic optionsFormation of CSCsGeneration of CSCsRole of dysregulationWnt/β-cateninStem cellsGastrointestinal neoplasmsTherapeutic optionsGastroesophageal tumorsGastrointestinal cancerTherapeutic strategiesTumor growthMalignant cellsMolecular abnormalitiesSignificant optimismCancerCancer resistanceΒ-cateninPatientsMalignancyTransformation growthPrecise targetingPotential utility
2013
Management of High-Risk Myelodysplastic Syndrome
Zeidan A, Gore S. Management of High-Risk Myelodysplastic Syndrome. Hematologic Malignancies 2013, 189-210. DOI: 10.1007/978-3-642-36229-3_12.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeHR-MDSDNMTi therapyDNA methyltransferase inhibitorEmergence of resistanceTherapeutic optionsMyelodysplastic syndromeNovel agentsAllogeneic hematopoietic stem cell transplantationCare first-line therapyHematopoietic stem cell transplantationDuration of therapyFirst-line therapyComplex pathogenetic mechanismsStem cell transplantationLimited therapeutic optionsGood responseMechanism of actionAzacitidine therapyStable diseaseHematologic improvementIntensive chemotherapyMaintenance therapyUntreated patientsMedian survival